Instil Bio, Inc. Deferred Offering Costs
Instil Bio, Inc. (TIL) had Deferred Offering Costs of $0 as of 2021-12-31, per its 10-K filed 2022-03-07.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2022-03-07
- 2021-12-31: Deferred Offering Costs $0.00.
- 2020-12-31: Deferred Offering Costs $500.00K.
| Period end | Deferred Offering Costs |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-07 |
| 2020-12-31 | $500.00K 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |